Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).Jessica Ley, D. Adkins, F. Dehdashti et al.|Journal of Clinical Oncology|2011Cited by 0